At least 16 biotechs and pharmas are slated to report earnings this week. Potential takeout target Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is expected to report 2Q13 EPS growth of 45% on a 33% increase in revenues to $365 million. Earlier this month rumors surfaced that Roche (SIX:ROG; OTCQX:RHHBY) was considering an acquisition of the biotech, which markets blood disorder drug Soliris eculizumab (see BioCentury, July 15).